Bioline RX News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.11.24	BioLineRx Signs A $10mln Upfront Deal With Ayrmid To Commercialise APHEXDA (RTTNews)
31.10.23	BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures (PR Newswire)
12.10.23	BioLineRx Concludes License Deal With Guangzhou Gloria To Develop Motixafortide In Asia (RTTNews)
11.09.23	BioLineRx: FDA Approves APHEXDA Plus Filgrastim To Mobilize Hematopoietic Stem Cells; Stock Up (RTTNews)
11.09.23	BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in... (PR Newswire)
31.08.23	Biotech Stocks Facing FDA Decision In September 2023 (RTTNews)
04.03.23	BLRX MONDAY DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important March 6 Deadline in Securities Class Action Filed by ... (PR Newswire)
25.02.23	BLRX IMPORTANT DEADLINE: ROSEN, A TOP RANKED FIRM, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 6 Deadline in Securities Class Action... (PR Newswire)
18.02.23	ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX (PR Newswire)
11.02.23	ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages BioLineRx Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX (PR Newswire)
04.02.23	ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX (PR Newswire)
27.01.23	ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX (PR Newswire)
21.01.23	ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX (PR Newswire)
13.01.23	BLRX NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm - BLRX (PR Newswire)
05.01.23	BLRX INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm ... (PR Newswire)
31.12.22	BLRX SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation - BLRX (PR Newswire)
20.12.22	BioLineRx : Phase 1/2a Study Of AGI-134 In Metastatic Solid Tumors Meets Primary Endpoint (RTTNews)
22.09.22	BLRX INVESTOR ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation - BLRX (PR Newswire)
12.09.22	BioLineRx Announces Submission Of Its First NDA - Quick Facts (RTTNews)
29.06.22	BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures (PR Newswire)
28.06.22	BioLineRx Collaborates With GenFleet To Advance Motixafortide In Pancreatic Ductal Adenocarcinoma (RTTNews)
17.12.21	BioLineRx Plans Pre-NDA Meeting For Motixafortide Plus G-CSF - Quick Facts (RTTNews)
13.10.21	BioLineRx: Pharmacoeconomic Study Shows Cost Benefits Of Using Motixafortide With G-CSF (RTTNews)
18.08.21	BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update (PR Newswire)
12.08.21	BioLineRx to Report Second Quarter 2021 Results on August 18, 2021 (PR Newswire)
21.01.21	PFE/BNTX Covid Jab Neutralizes UK Strain, Pura Vida Ups Stake In OCX, Woodcock Is Interim FDA Chief (RTTNews)
20.01.21	Pre-market Movers In Healthcare Sector: LCTX, DARE, SRNE, NOVN, HSTO… (RTTNews)
16.12.20	BioLineRx Reports Results From Phase 2a Combination Study Of Motixafortide (RTTNews)
24.11.20	AZN's COVID Shot 70% Effective On Average, ARQT Aces Scalp Psoriasis Study, BLRX' BLAST Fizzles (RTTNews)
03.11.20	Pre-market Movers In Healthcare Sector: DBVT, ACOR, ANPC, AGRX, CATB… (RTTNews)
02.11.20	Pre-market Movers In Healthcare Sector: DBVT, BLRX, VTVT, SRNE, EQ... (RTTNews)
20.08.20	JNJ Acquires MNTA, FDA Strikes Down BMRN's Gene Therapy, BLRX's GENESIS On Track, TPTX On Watch (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Bioline RX Ltd (spons. ADRs)

Aktien Top/Flop

Meistgelesene Nachrichten